Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats

被引:87
作者
Aksu, Ali Emre [1 ]
Horibe, Elaine [1 ]
Sacks, Justin [1 ]
Ikeguchi, Ryosuke [1 ]
Breitinger, Jeremy [1 ]
Scozio, Merissa [1 ,2 ]
Unadkat, Jignesh [1 ]
Feili-Hariri, Maryam [1 ]
机构
[1] Univ Pittsburgh, Dept Surg, Sch Med, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Dept Immunol, Sch Med, Pittsburgh, PA 15261 USA
关键词
rat; mesenchymal stem cells; bone marrow; GVHD; vascularized skin;
D O I
10.1016/j.clim.2008.02.003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We investigated the effect of autologous mesenchymal stem cells (MSC) on multiple unmodified donor bone marrow (BM) infusions and vascularized skin graft outcome. BM-derived rat MSC were examined for phenotype and function. MSC/MSC-conditioned-medium suppressed IFN-gamma production by T cells and modified DC function. Infusions of MSC with one-time BM improved vascularized skin graft survival, while with one-two-times BM reversed graft versus host disease (GVHD). Mixed chimerism was enhanced in recipients given two-four-times BM with MSC infusions. Interestingly, four-times BM infusions with MSC delayed GVHD onset, reduced host tissue damage and enhanced vascularized skin allograft survival compared to four-times BM alone. These data demonstrate that, the co-infusion of MSC with unmodified BM limit the toxicity of allogeneic BM transplantation, enhance mixed chimerism and improve vascularized skin graft survival. These findings provide insights for the development of autologous MSC-based BM transplantation and prevention of graft rejection or treatment of autoimmunity.(c) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:348 / 358
页数:11
相关论文
共 52 条
[1]   Human mesenchymal stem cells modulate allogeneic immune cell responses [J].
Aggarwal, S ;
Pittenger, MF .
BLOOD, 2005, 105 (04) :1815-1822
[2]  
ALLISON AC, 1993, SPRINGER SEMIN IMMUN, V14, P353
[3]   Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo [J].
Bartholomew, A ;
Sturgeon, C ;
Siatskas, M ;
Ferrer, K ;
McIntosh, K ;
Patil, S ;
Hardy, W ;
Devine, S ;
Ucker, D ;
Deans, R ;
Moseley, A ;
Hoffman, R .
EXPERIMENTAL HEMATOLOGY, 2002, 30 (01) :42-48
[4]   SEQUENTIAL MORPHOLOGY OF GRAFT VERSUS HOST-DISEASE IN THE RAT RADIATION CHIMERA [J].
BESCHORNER, WE ;
TUTSCHKA, PJ ;
SANTOS, GW .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1982, 22 (02) :203-224
[5]   Recent advances in graft-versus-host disease (GVHD) prevention [J].
Blazar, BR ;
Korngold, R ;
Vallera, DA .
IMMUNOLOGICAL REVIEWS, 1997, 157 :79-109
[6]   What does the future hold for cell-based tolerogenic therapy? [J].
Bluestone, Jeffrey A. ;
Thomson, Angus W. ;
Shevach, Ethan M. ;
Weiner, Howard L. .
NATURE REVIEWS IMMUNOLOGY, 2007, 7 (08) :650-654
[7]   Mesenchymal stem cells as trophic mediators [J].
Caplan, Arnold I. ;
Dennis, James E. .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2006, 98 (05) :1076-1084
[8]   Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome [J].
Chapel, A ;
Bertho, JM ;
Bensidhoum, M ;
Fouillard, L ;
Young, RG ;
Frick, J ;
Demarquay, C ;
Cuvelier, F ;
Mathieu, E ;
Trompier, F ;
Dudoignon, N ;
Germain, C ;
Mazurier, C ;
Aigueperse, J ;
Borneman, J ;
Gorin, NC ;
Gourmelon, P ;
Thierry, D .
JOURNAL OF GENE MEDICINE, 2003, 5 (12) :1028-1038
[9]  
COLSON YL, 1995, J IMMUNOL, V155, P4179
[10]   Mesenchymal stem cells: Biology and potential clinical uses [J].
Deans, RJ ;
Moseley, AB .
EXPERIMENTAL HEMATOLOGY, 2000, 28 (08) :875-884